1332 Stock Overview
Touyun Biotech Group Limited, an investment holding company, designs, develops, manufactures, and sells packaging products in Hong Kong, the People’s Republic of China, Europe, North and South America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Touyun Biotech Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.24 |
| 52 Week High | HK$0.68 |
| 52 Week Low | HK$0.13 |
| Beta | -0.72 |
| 1 Month Change | 3.04% |
| 3 Month Change | 31.67% |
| 1 Year Change | -64.09% |
| 3 Year Change | -79.57% |
| 5 Year Change | -59.42% |
| Change since IPO | 4.31% |
Recent News & Updates
Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?
Apr 08
What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You
Feb 07Recent updates
Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?
Apr 08What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You
Feb 07Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding
Dec 18Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt
Sep 19Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)
Jul 28Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt
Sep 13Touyun Biotech Group (HKG:1332) Is Making Moderate Use Of Debt
May 18Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt
Dec 24Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?
Mar 12If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns
Jan 15
The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares
Jan 15How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?
Dec 11Shareholder Returns
| 1332 | HK Packaging | HK Market | |
|---|---|---|---|
| 7D | 3.0% | -0.6% | 0.9% |
| 1Y | -64.1% | 6.6% | -14.1% |
Return vs Industry: 1332 underperformed the Hong Kong Packaging industry which returned 6.6% over the past year.
Return vs Market: 1332 underperformed the Hong Kong Market which returned -14.1% over the past year.
Price Volatility
| 1332 volatility | |
|---|---|
| 1332 Average Weekly Movement | 15.5% |
| Packaging Industry Average Movement | 6.9% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 1332's share price has been volatile over the past 3 months.
Volatility Over Time: 1332's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 566 | Amy Ha | touyunbiotech.com.hk |
Touyun Biotech Group Limited, an investment holding company, designs, develops, manufactures, and sells packaging products in Hong Kong, the People’s Republic of China, Europe, North and South America, and internationally. It operates through four segments: QR Code Business, Packaging Products Business, Treasury Investment Business, and Chlamydomonas Reinhardtii Products Business. The QR Code Business segment provides QR codes on product packaging and solutions, and advertising display services.
Touyun Biotech Group Limited Fundamentals Summary
| 1332 fundamental statistics | |
|---|---|
| Market cap | HK$665.01m |
| Earnings (TTM) | -HK$268.94m |
| Revenue (TTM) | HK$198.64m |
3.3x
P/S Ratio-2.5x
P/E RatioIs 1332 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1332 income statement (TTM) | |
|---|---|
| Revenue | HK$198.64m |
| Cost of Revenue | HK$144.77m |
| Gross Profit | HK$53.88m |
| Other Expenses | HK$322.81m |
| Earnings | -HK$268.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | 27.12% |
| Net Profit Margin | -135.39% |
| Debt/Equity Ratio | 1,691.0% |
How did 1332 perform over the long term?
See historical performance and comparison